相关实验视频
Updated: Sep 19, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.5K
阿尔茨海默氏症中的热:机制和治疗潜力
1Department of Laboratory Medicine, People's Hospital of Deyang City, No. 173, Section 1, Taishan North Road, Jingyang District, Deyang, 618000, Sichuan Province, P. R. China. TianT5829@163.com.
Cellular and molecular neurobiology
|June 17, 2025
概括
炎症性细胞死亡的 Pyroptosis 驱动着阿尔茨海默病 (AD) 的进展. 准这种途径,包括炎症体和体,为病理修饰AD治疗提供了新的希望.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是由粉样质斑块,神经纤维状结和神经炎症标志着.
- 炎症性编程细胞死亡 (PCD) 的一种形式,热,越来越被认为是AD病理学的关键贡献者.
- 粉样β,蛋白和火的相互作用会产生一种有害的神经炎症-神经退行周期.
研究的目的:
- 审查热在阿尔茨海默氏症病原发生中的作用.
- 探索针对阿尔茨海默病治疗的热致死途径的治疗策略.
- 突出灭酶抑制对疾病修饰的潜力.
主要方法:
- 关于研究阿尔茨海默病中热的研究的文献综述.
- 对治疗干预的分析,这些干预的目标是像炎症体,卡斯帕-1和气皮素D (GSDMD) 这样的皮质灭绝信号元件.
- 检查目前的局限性和未来的研究方向在 pyroptosis 向的AD疗法.
主要成果:
- 由Aβ和tau触发的灭酶激活会释放炎症性细胞因子,加剧神经退行.
- 抑制关键的热致死介质 (炎症体,卡斯帕酶-1,GSDMD) 显示出缓解AD病理的潜力.
- 现有的灭酶抑制剂缺乏特异性,而非经典的途径需要进一步研究.
结论:
- 向热的途径为阿尔茨海默病提供了一个新的治疗途径.
- 对于有效的病理修饰治疗,进一步研究热灭机制和抑制剂的开发至关重要.
- 这种方法在阿尔茨海默病治疗中提供了一个有希望的转变,从症状管理到疾病修改.
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686
Parkinson's Disease: Overview
723
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
723
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K

